Corline Biomedical AB (CLBIO.ST)
Corline Biomedical AB operates in the Biotechnology industry of the Healthcare sector, headquartered in Uppsala, UP, SE. The stock last traded at $14.15, down 0.35% on the session, giving a market capitalisation of $369.8M. Its beta of 0.29 implies it has historically moved less than the broad market.
Corline Biomedical AB is a company dedicated to the creation, production, and distribution of heparin-based solutions. These solutions are specifically engineered to enhance outcomes in kidney transplantation, cellular therapies, and regenerative medicine. At the heart of their product line is the proprietary Corline Heparin Conjugate (CHC) technology, a unique heparin conjugate that can function as a standalone pharmaceutical compound. The company's diverse portfolio includes Renaparin, aimed at treating end-stage renal failure; Cytoparin, a cell therapy designed for patients with type 1 diabetes; the CHC compound itself for addressing soft tissue injuries; and a variety of medical devices, such as CHS, a coronary stent. Established in 1991, Corline Biomedical AB operates from its headquarters in Uppsala, Sweden.
Corline Biomedical AB is most often compared with the following Healthcare names: